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Background. Bulimia nervosa (BN) is a serious psychiatric disorder characterized by frequent episodes of binge
eating and inappropriate compensatory behavior. Numerous trials have found that antidepressant medications are
efficacious for the treatment of BN. Early response to antidepressant treatment, in the first few weeks after medication
is initiated, may provide clinically useful information about an individual’s likelihood of ultimately benefitting or not
responding to such treatment. The purpose of this study was to examine the relationship between initial and later
response to fluoxetine, the only antidepressant medication approved by the US Food and Drug Administration (FDA)
for the treatment of BN, with the goal of developing guidelines to aid clinicians in deciding when to alter the course
of treatment.
Method. Data from the two largest medication trials conducted in BN (n=785) were used. Receiver operating
characteristic (ROC) curves were constructed to assess whether symptom change during the first several weeks of
treatment was associated with eventual non-response to fluoxetine at the end of the trial.
Results. Eventual non-responders to fluoxetine could be reliably identified by the third week of treatment.
Conclusions. Patients with BN who fail to report a o60% decrease in the frequency of binge eating or vomiting at
week 3 are unlikely to respond to fluoxetine. As no reliable relationships between pretreatment characteristics and
eventual response to pharmacotherapy have been identified for BN, early response is one of the only available
indicators to guide clinical management.
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Introduction
Bulimia nervosa (BN) is a serious psychiatric disorder
characterized by frequent episodes of binge eating and
inappropriate compensatory behavior. Numerous
trials have found that antidepressant medications,
including both tricyclic antidepressants (TCAs) and
selective serotonin reuptake inhibitors (SSRIs), pro-
duce consistently superior reductions in bulimic symp-
toms than those achieved with placebo (Shapiro et al.
2007). Although TCAs and SSRIs seem to have
roughly equal efficacy, SSRI antidepressants have
fewer side-effects and are better tolerated (Zhu &
Walsh, 2002). Fluoxetine, an SSRI, is the only anti-
depressant currently approved by the US Food and
Drug Administration (FDA) for the treatment of BN.
Two large multi-site studies, sponsored by Eli Lilly &
Company, evaluated fluoxetine for the treatment of
BN, and found that fluoxetine at 60 mg/day produced
significantly greater reductions in bulimic symptoms
when compared to fluoxetine 20 mg/day and placebo
(Fluoxetine Bulimia Nervosa Collaborative Study
Group, 1992 ; Goldstein et al. 1995).
In general, it has proven difficult to identify reliable
pretreatment predictors of response to psychiatric
treatments. However, in recent years, an increasing
number of studies have examined early or rapid
response to treatment as an indicator of eventual re-
sponse. Early response refers to the change in symp-
toms during the first several weeks of treatment and
rapid response, or ‘sudden gains ’, denotes a quick
and clinically meaningful change in symptoms. Across
psychiatric disorders such as mood and anxiety dis-
orders, psychosis and eating disorders, early or rapid
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response can be useful in predicting treatment out-
come (e.g. Grilo & Masheb, 2007 ; Masheb & Grilo,
2007 ; Kinon et al. 2008 ; le Grange et al. 2008 ; Pollack
et al. 2008 ; Szegedi et al. 2009 ; Tao et al. 2009). In
addition, for patients with eating disorders, early and
rapid response are robust predictors of short- and
long-term response to cognitive-behavioral therapy
(CBT; Wilson et al. 1999, 2002 ; Agras et al. 2000 ;
Fairburn et al. 2004; Grilo & Masheb, 2007 ; Kaplan
et al. 2009). However, data on response to anti-
depressant medications are more limited. An analysis
of rapid response among patients with binge eating
disorder found that non-response to medication
(fluoxetine or placebo) in the first 4 weeks of treatment
was associated with later non-response (Grilo et al.
2006). Grilo et al. (2006) also observed that patients
who did not demonstrate an early rapid response to
CBT continued to improve throughout treatment
whereas initial non-responders to medication experi-
enced limited additional benefit from fluoxetine or
placebo. Another study suggested that patients with
BN who will not respond to antidepressant medi-
cation can be reliably identified early in treatment
(Walsh et al. 2006). Specifically, 80–85% of patients
would be correctly identified as eventual non-
responders to desipramine by the second week of
treatment. However, this study had several important
limitations, including the relatively small sample of
patients with BN (n=77), and the now infrequent use
of desipramine to treat BN.
Decreases in binge eating and purging may be evi-
dent among patients with BN in the first few weeks
after antidepressant treatment is initiated. However,
there are no guidelines for clinicians to indicate
when the response should be declared inadequate and
the treatment terminated (Sadock & Sadock, 2007),
and recommendations for prescribing antidepressants
to patients with BN often omit information about
the time course for discontinuing these medications
(Becker et al. 2008 ; Walsh, 2008). The ability to rec-
ognize non-response rapidly would substantially
enhance clinical management. Alternative psycho-
logical and pharmacological treatments could be im-
plemented, reducing the delay to symptom relief
and patient withdrawal from treatment because of
frustration over lack of response. Thus, the purpose
of the current study was to examine the response
to antidepressant medication in the largest treat-
ment trials conducted for BN (Fluoxetine Bulimia
Nervosa Collaborative Study Group, 1992 ; Goldstein
et al. 1995) to determine whether clinically useful
guidelines can be developed to predict eventual
non-response to fluoxetine on the basis of sympto-




Data for the current study were provided by Eli Lilly
and Company from two previously published studies
of fluoxetine (Fluoxetine Bulimia Nervosa Collabora-
tive Study Group, 1992 ; Goldstein et al. 1995) for the
treatment of DSM-III-R BN. The first study (Fluoxetine
Bulimia Nervosa Collaborative Study Group, 1992)
randomly assigned patients with BN to either fluox-
etine (20 or 60 mg/day) or placebo at 13 sites in the
USA and Canada. A total of 387 patients participated
in the study: 129 receiving placebo, 129 receiving
20 mg fluoxetine, and 129 receiving 60 mg fluoxetine).
The second study (Goldstein et al. 1995) enrolled
patients at 15 sites across the USA, and examined
fluoxetine at a 60 mg/day dosage in comparison to
placebo. Two hundred and ninety-six patients were
randomly assigned to receive fluoxetine and 102
patients to receive placebo for 16 weeks. Thus, the
sample for this study included a total of 785 patients :
231 receiving placebo and 554 receiving fluoxetine
(n=129 fluoxetine 20 mg; n=425 fluoxetine 60 mg).
As the 1992 trial was only 8 weeks in duration, our
primary analyses were limited to the first 8 weeks of
antidepressant treatment.
The inclusion and exclusion criteria for the two
studies were very similar. Patients in both studies
were at least 18 years of age andmet DSM-III-R criteria
for BN (APA, 1987). Although twice-weekly episodes
of binge eating over the prior 3 months are required by
DSM-III-R and DSM-IV (APA, 2000) for a diagnosis of
BN, these studies included patients with more severe
symptoms. Specifically, individuals needed to report
at least three episodes of binge eating weekly for the
prior 6 months. Mean ages and body weights between
the studies were very similar (1992 study: 27.2 years
and 60.6 kg; 1995 study: 26.7 years and 58.0 kg). The
1992 study included only women and the 1995 study
included 15 (1.9%) men. Both studies assessed binge
eating and vomiting frequencies using a self-report
weekly measure of binge eating and vomiting.
As the data provided by Eli Lilly and Company
were completely anonymous, this project did not
constitute human subjects research according to the
federal definition [45CFR46.102(f)], and therefore
approval by the Institutional Review Board was not
required for this study.
Statistical analyses
Receiver operating characteristic (ROC) curves were
constructed to assess whether symptom change dur-
ing the first several weeks of treatment predicted
eventual non-response to fluoxetine at the end of the
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trial. ROC curves provide a graphical display of the
accuracy of a measure (e.g. number of binge episodes
in the first 4 weeks of treatment) in correctly predict-
ing an outcome (e.g. non-response to treatment at
weeks 7 and 8). All possible values for ‘hits ’ (sensi-
tivity) and ‘false alarms’ (1 – specificity) are plotted
for various thresholds of the measure, and the ROC
curve can be examined to optimize the trade-off
between sensitivity and specificity (McFall & Treat,
1999). The ROC curves were used to assess the associ-
ation between the change in symptoms (binge eating
and vomiting) at weeks 1–4 and the primary binary
outcome measure (responder or non-responder).
The primary ROC analyses used the entire patient
sample, pooled across treatment arms, to predict non-
response defined as the failure to achieve at least a
75% reduction in symptoms at weeks 7 and 8. Non-
response was chosen as the primary outcome because
patients who fail to respond and require a change in
treatment are the more clinically important group to
identify. The criterion of a 75% reduction in symptoms
has been used as an outcome in other medications
studies of BN (Pope et al. 1983 ; Walsh et al. 1987 ;
Fluoxetine Bulimia Nervosa Collaborative Study
Group, 1992 ; Goldstein et al. 1995) and allowed for
comparisons with our earlier study of early response
to desipramine (Walsh et al. 2006). Furthermore,
although abstinence is an important goal for a full
course of treatment for BN, a 75% reduction is a
clinically significant change in the first 7 or 8 weeks of
treatment. In the previous analysis of early response
(Walsh et al. 2006), similar results were obtained
for ROC analyses restricted to individuals receiving
medication and analyses including both medication
and placebo. Thus, we used the entire sample for our
primary analyses and examined differences between
treatment groups (20 mg fluoxetine, 60 mg fluoxetine,
placebo) in secondary analyses. The area under the
curve (AUC) was calculated for each ROC curve. The
AUC measures the overall accuracy of the prediction,
or how well the prediction separates the group being
tested into those with and without the outcome in
question (response versus non-response). As a general
guideline, an AUC of 0.5 provides no discrimination
(e.g. chance), AUCs between 0.7 and 0.8 are con-
sidered acceptable, AUCs between 0.8 and 0.90 are
considered excellent, and AUCs>0.9 are considered
outstanding (Hosmer & Lemeshow, 2000).
We conducted a variety of secondary analyses. First,
ROC curves were constructed using alternative out-
comes, including the prediction of other levels of re-
sponse commonly used in studies of BN, including the
failure to achieve at least a 50% decline or a 100% de-
cline (full abstinence) from baseline. Second, separate
ROC curves were derived for patients assigned to 20
and 60 mg of fluoxetine and placebo, and the data
from the 1992 and 1995 studies. Third, we applied the
method of Obuchowski (2006), which generalizes the
usual dichotomous ROC analysis to examine changes
in the number of episodes of binge eating and vomi-
ting as continuous outcome measures. Fourth, we
analyzed the frequency of participants’ binge eating
and vomiting during weeks 7 and 8 using a Poisson
regression with the following predictors : vomiting
frequency at week 4; ethnicity ; baseline body mass
index (BMI). We allowed for possible overdispersion
and estimated scale parameters using Pearson’s x2
statistic. Finally, we examined ROC curves predicting
the failure to achieve a 75% decline from baseline
among the subset of patients who received a longer
course of treatment (outcome=average of weeks 15
and 16).
Results
Among the 785 patients randomized to medication or
placebo, the average age of the patients was 28.0¡7.8
(range 17.0–63.0) years and mean BMI was 22.3¡3.7
(range 15.9–45.7) kg/m2.
Missing data
A total of four patients (1992 study, n=1 placebo
group; 1995 study, n=3 fluoxetine 60 mg) reported
no binge eating episodes at baseline, 67 (n=66 1992
study: n=26 placebo, n=20 fluoxetine 20 mg, n=20
fluoxetine 60 mg; 1995 study, n=1 placebo group) re-
ported no vomiting at baseline, and one patient (1992
study, placebo) reported neither binge eating nor
vomiting. The Fluoxetine Bulimia Nervosa Collabora-
tive Study Group (1992) reported that 67 of 387
patients enrolled in the study did not use self-induced
vomiting as their primary compensatory behavior.
These individuals reported abuse of laxatives or
diuretics, fasting, strict dieting or rigorous exercise,
with many patients indicating the use of more than
one method to prevent weight gain. Thus, the number
of patients who did not report vomiting episodes at
baseline in the 1992 study may be explained by the use
of other forms of inappropriate compensatory behav-
ior. It is not entirely clear why other patients (n=6)
reported no binge eating or vomiting at baseline ;
however, this may be related to reactivity, including
the timing of the baseline assessment, which occurred
post-placebo wash-out, or the time-frame for the
measurement, which was only the prior week. The 72
individuals without binge eating or vomiting at base-
line were excluded from the ROC analyses described
below, resulting in an initial sample of 713 patients.
Among these 713 patients, the average number of binge
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eating episodes was 11.5¡11.2 (range 1.0–150.0) and
the average number of vomiting episodes per week
was 13.6¡16.5 (range 1.0–225.0).
Primary analysis : predicting non-response at weeks
7 and 8
ROC curves predicted non-response at weeks 7 and 8
using the percentage change in binge eating or vomi-
ting during the first 4 weeks of the study. Missing data
are excluded from the fitting of ROC curves. At weeks
7 and 8, a total of 557 and 510 patients had data on
binge eating frequency and vomiting respectively.
A total of 375 patients (67.3%; n=108 placebo; n=74
fluoxetine 20 mg; n=193 fluoxetine 60 mg) failed to
show ao75% decrease in binge eating at weeks 7 and
8, and 348 (68.2%; n=100 placebo; n=56 fluoxetine
20 mg; n=192 fluoxetine 60 mg) were classified as
non-responders for vomiting. Similar results were ob-
tained when the ROC curves were fitted separately
by treatment arms (placebo, fluoxetine 20 mg, or
fluoxetine 60 mg), and by study (1992 or 1995). Data
from the combined sample are presented in Fig. 1.
In the ROC analysis, the AUC indicates the accuracy
of the prediction (Table 1). Starting with the week 3
data, the AUCs were in the excellent range (0.808 for
binge eating, 0.815 for vomiting). Only the ROC curves
constructed from data at week 4 had greater AUCs
(0.828 for binge eating, 0.819 for vomiting), but these
AUCs were still in the excellent range (Hosmer &
Lemeshow, 2000), suggesting that the accuracy of the
prediction from response at the fourth week of treat-
ment was not substantially better. A large proportion
of the patients who would fail to respond to medi-
cation by weeks 7 and 8 would be correctly classified
by week 3. If medication was discontinued for patients
who failed to demonstrate a reduction in binge eating
of approximately 60% at week 3, our analyses indicate
that 78% of patients who would have failed to respond
to medication would be correctly identified (sensi-
tivity), and 27.5% who would have responded to
medication at weeks 7 and 8 would be misclassified as
non-responders (1 – specificity). A similar pattern was
observed for vomiting ; with a cut-point of a decrease
in vomiting of approximately 60% at week 3, 79%
of the eventual non-responders would be correctly
classified as failing to respond to fluoxetine and 26%
of eventual responders would be misclassified as non-
responders.
Secondary analyses
Secondary ROC analyses predicting 50% and 100%
reduction in binge eating and vomiting at week 8
found similar results to the analyses using 75% re-
sponse. Specifically, the AUCs for week 3 were in the
acceptable range when predicting a 100% reduction in
binge eating (0.778), and in the excellent range when
predicting a 50% reduction in binge eating (0.819)
or vomiting (0.819), or a 100% response for vomiting
(0.824). Exploratory analyses using the method of
Obuchowski (2006) for a continuous outcome for
binge eating and vomiting did not produce more ac-
curate predictions than the dichotomous indicator of
response or non-response based on a 75% reduction
in bulimic symptoms. The Poisson model, which in-
cluded additional predictors, produced an ROC curve
with an AUC slightly better than the AUCs for the
percentage change in binge eating or vomiting at
the first or second week of treatment, and similar to
Reference line
% change vomiting week 1
% change vomiting week 2
% change vomiting week 3


























% change binge eating week 1
% change binge eating week 2
% change binge eating week 3
% change binge eating week 4
(a) (b)
Fig. 1. Receiver operating characteristic (ROC) curves predicting the failure to achieve a o75% reduction in (a) binge eating
or (b) vomiting by weeks 7 and 8 based on the change in symptoms from baseline during the first 4 weeks of treatment.
1002 R. Sysko et al.
AUCs observed for change in binge eating or vomiting
at the third or fourth weeks of treatment. A subset of
patients had data on binge eating (n=327) and vomi-
ting (n=304) at weeks 15 and 16. The ROC curves for
the longer-term response identified week 3 as the most
accurate in predicting non-response (AUC=0.763 for
binge eating, 0.757 for vomiting). A cut-point of ap-
proximately 60% at week 3 would identify 69% and
68% of the eventual non-responders for binge eating
and vomiting respectively, and 28% and 30% of
eventual responders would be misclassified as non-
responders respectively.
Discussion
The aim of the current study was to evaluate whether
clinically useful guidelines could be developed to
predict eventual non-response to fluoxetine on the
basis of response during the first several weeks of
treatment using the largest extant sample of patients
with BN (Fluoxetine Bulimia Nervosa Collaborative
Study Group, 1992; Goldstein et al. 1995). The results
suggest that a majority of patients with BN who will
not respond to fluoxetine can be identified early in
treatment, specifically by the third week. At week 3,
if fluoxetine was discontinued for patients who dem-
onstrated less than a 60% reduction in binge eating,
approximately 73% would be correctly classified as
eventual non-responders to fluoxetine and 23% of
patients who would eventually respond to fluoxetine
would be misclassified as non-responders. For
patients with less than a 60% decrease in vomiting
at week 3, approximately 72% would be correctly
classified as non-responders and 22% would be mis-
classified.
These data, in combination with the findings of our
previous research (Walsh et al. 2006), suggest that
eventual antidepressant treatment response in BN can
be reasonably predicted from change in symptoms
during the first several weeks of treatment. Further-
more, these results are consistent with studies of
CBT in randomized controlled trials of adults with BN
(NICE, 2004). Studies by Wilson et al. (1999, 2002)
suggest that response to CBT in BN begins in the first
few weeks after the initiation of treatment, and early
response to CBT is also predictive of longer-term out-
come (Fairburn et al. 2004). However, although early
response is a reliably observed predictor of response
to psychological and pharmacological treatments for
patients with BN, the mechanisms of this phenomenon
are not known.
The results of the current study also suggest appli-
cations for the clinical treatment of BN. Some patients
with BNmay be reluctant to take a medication (Wilson
& Fairburn, 2007) but might be willing to consider a
brief trial of fluoxetine to evaluate whether they are
likely to eventually respond to antidepressant treat-
ment. The ability to make rapid adjustments to the
course of treatment if a patient does not experience a
50% reduction in symptoms by the third week might
improve treatment efficacy and compliance. Although
approximately 20% of non-responders are mis-
classified at week 3 using the 50% criterion, clinicians
might still consider switching to another medication
treatment or CBT at week 3 to evaluate whether a dif-
ferent intervention might provide greater symptom
relief.
There are several limitations to the current study,
including the use of retrospective analyses, and the
use of criterion for response was based on data from a
self-report daily diary and not an interview. In ad-
dition, as the analyses examined non-response only
during acute treatment and not over a follow-up
period, the findings may not generalize over longer
periods of time or following the discontinuation of
fluoxetine. Finally, this study focused on patients
Table 1. Areas under the curve for binge eating and vomiting at each week of treatment
AUC S.E.
Binge eating
% Change in binge eating from baseline to week 1 0.647 0.025
% Change in binge eating from baseline to week 2 0.756 0.023
% Change in binge eating from baseline to week 3 0.808 0.020
% Change in binge eating from baseline to week 4 0.828 0.020
Vomiting
% Change in vomiting from baseline to week 1 0.695 0.026
% Change in vomiting from baseline to week 2 0.739 0.025
% Change in vomiting from baseline to week 3 0.815 0.021
% Change in vomiting from baseline to week 4 0.819 0.021
AUC, Area under the curve ; S.E., standard error.
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reporting vomiting as their primary means of com-
pensation, and the results may be different for in-
dividuals with BN using other types of purging
behaviors (e.g. laxatives). Strengths of the current
study include the sample size, the consistency of the
findings regardless of the cut-point or end-point (7–8
weeks v. 15–16 weeks) used for eventual response,
and the examination of response to fluoxetine, the only
medication currently approved by the FDA for the
treatment of BN.
In summary, this study focused on early response
to fluoxetine among patients with BN. By the third
week of treatment, the majority of patients who will
eventually fail to respond to fluoxetine can be ident-
ified with reasonable accuracy, and the medication can
be discontinued for individuals who have not experi-
enced a o60% reduction in bulimic symptoms. As no
reliable relationships between pretreatment charac-
teristics and eventual response to pharmacotherapy
have been identified, early response is one of the only
available indicators to guide clinical management.
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